What is Zacks Small Cap’s Estimate for PLX FY2025 Earnings?

Protalix BioTherapeutics, Inc. (NYSE:PLX) – Zacks Small Cap lowered their FY2025 EPS estimates for shares of Protalix BioTherapeutics in a note issued to investors on Tuesday, March 18th. Zacks Small Cap analyst J. Vandermosten now forecasts that the company will post earnings per share of $0.43 for the year, down from their previous forecast of $0.44. The consensus estimate for Protalix BioTherapeutics’ current full-year earnings is $0.01 per share.

A number of other research firms also recently weighed in on PLX. StockNews.com downgraded Protalix BioTherapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday. HC Wainwright increased their price target on Protalix BioTherapeutics from $10.00 to $15.00 and gave the company a “buy” rating in a research note on Monday, February 3rd.

Protalix BioTherapeutics Stock Performance

Shares of NYSE PLX opened at $2.36 on Thursday. The stock has a market cap of $173.78 million, a P/E ratio of -18.15 and a beta of 0.72. The firm has a 50 day moving average price of $2.39 and a two-hundred day moving average price of $1.74. Protalix BioTherapeutics has a 52-week low of $0.82 and a 52-week high of $2.76.

Institutional Investors Weigh In On Protalix BioTherapeutics

Several large investors have recently modified their holdings of PLX. Y Intercept Hong Kong Ltd acquired a new position in Protalix BioTherapeutics in the fourth quarter valued at $35,000. XTX Topco Ltd bought a new position in shares of Protalix BioTherapeutics in the 3rd quarter worth about $36,000. Sanctuary Advisors LLC acquired a new position in shares of Protalix BioTherapeutics in the 3rd quarter valued at about $38,000. PFG Investments LLC acquired a new position in shares of Protalix BioTherapeutics in the 4th quarter valued at about $39,000. Finally, Virtu Financial LLC bought a new stake in shares of Protalix BioTherapeutics during the 3rd quarter valued at about $44,000. 16.53% of the stock is currently owned by institutional investors and hedge funds.

About Protalix BioTherapeutics

Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.